Hieronder staan alle publicaties die zijn voortgekomen uit BlaZIB, en de congressen en/of symposia waarop onderzoek van BlaZIB is gepresenteerd. Onderstaande lijst wordt aangevuld op het moment dat er nieuwe publicaties verschijnen of presentaties zijn gehouden.
Publicaties BlaZIB
- Richters et al., Staging fluorodeoxyglucose positron emission tomography / computed tomography for muscle-invasive bladder cancer: a nationwide population-based study. BJUI. 2023
- van Hoogstraten et al., Low guideline adherence to recommended use of neoadjuvant chemotherapy in patients with non-metastatic muscle-invasive bladder cancer. WJU. 2023
- Nuijens et al., Minimum volume standards: an incentive to perform more radical cystectomies? Eur Urol Open Sci. 2023
- de Haar-Holleman, van Hoogstraten et al., Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study. Radiother Oncol. 2023
- Ripping et al., Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer. Health Qual Life Outcomes. 2022
- van Hoogstraten et al., The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. Bladder Cancer. 2022
- Walraven et al., The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer. BJUI. 2022
- van Hoogstraten et al., Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent. BJUI. 2022
- van Hoogstraten, van Gennep et al., Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients. WJU. 2021
- Ripping et al., Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer. J Patient Rep Outcomes. 2021
- van Hoogstraten et al., Low risk of severe complications after a single, post-operative instillation of intravesical chemotherapy in patients with TaG1G2 urothelial bladder carcinoma. Bladder Cancer. 2021
- Richters et al., Hospital volume is associated with postoperative mortality following radical cystectomy for treatment of bladder cancer. BJU Int. 2021
- Ripping et al., Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. Urol Oncol. 2020
- Ripping et al., Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB). BMC Cancer. 2020
Congressen/symposia
- BUMC (maart 2023) – Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study
- Symposium COVID en kanker (december 2022) – De impact van de COVID-19 uitbraak op de blaaskankerzorg in Nederland
- BLADDR (oktober 2022) – Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
- BLADDR (oktober 2022) – Concurrent chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study
- ASTRO (oktober 2022) – Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder preserving therapy: a nationwide study
- NKR symposium (oktober 2022) – Concurrent chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study
- NKR symposium (oktober 2022) – Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
- V&VN masterclass urologie (oktober 2022) – BlaZIB & kwaliteit van leven bij blaascarcinoom
- IBCN (september 2022) – Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
- IBCN (september 2022) – Concurrent chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study
- WEON (juni 2022) – Low guideline adherence to recommended use of neoadjuvant chemotherapy in patients with non-metastatic muscle-invasive bladder cancer
- NKR symposium (november 2021) – Centralisatie chirurgische behandeling en postoperatieve mortaliteit bij blaaskanker, resultaten uit de BlaZIB-studiegroep
- NKR symposium (november 2021) – The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands
- NKR symposium (november 2021) – Part of untreated patients with non-metastatic muscle invasive bladder is wrongfully denied life prolonging treatment
- ENCR (november 2021) – The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands
- IACR (oktober 2021) – The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands
- EAU21 (juli 2021) – Very low risk of severe complications after a single, post-operative instillation of intravesical chemotherapy in patients with low- or intermediate risk urothelial carcinoma of the bladder
- EAU21 (juli 2021) – Characteristics and survival of untreated versus treated patients with non-metastatic muscle invasive bladder cancer
- WEON (juni 2021) – Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer
- WEON (juni 2021) – Characteristics and survival of untreated versus treated patients with non-metastatic muscle invasive bladder cancer
- SONCOS (februari 2021) – Stand van zaken BlaZIB, resultaten van lopende onderzoeken samengevat en work in progress
- Global Conference on Bladder Cancer (BLADDR) (oktober 2020) – Very low risk of severe complications after a single, post-operative instillation of intravesical chemotherapy in patients with low- or intermediate risk urothelial carcinoma of the bladder